MetaNovas, a pioneer in commercializing AI-designed molecular materials, secures Series A+ and A++ funding from investors including Fuhua Capital and Hillhouse Capital. Its Agentic AI R&D system enables full-cycle development from molecule design to real-world production, with compliant new materials already entering supply chains for top cosmetic and medical device brands in China and the U.S., shortening development cycles and targeting niche consumer health markets.